Cryoport, Inc. (NASDAQ:CYRX – Get Free Report) insider Mark W. Sawicki sold 1,367 shares of Cryoport stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $17.54, for a total value of $23,977.18. Following the sale, the insider now directly owns 77,444 shares in the company, valued at approximately $1,358,367.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cryoport Price Performance
Shares of NASDAQ:CYRX opened at $18.12 on Thursday. Cryoport, Inc. has a 12 month low of $9.00 and a 12 month high of $24.30. The stock has a market cap of $887.52 million, a price-to-earnings ratio of -8.24 and a beta of 1.61. The stock’s 50 day moving average price is $15.95 and its 200 day moving average price is $14.37. The company has a debt-to-equity ratio of 0.82, a current ratio of 11.73 and a quick ratio of 11.16.
Institutional Investors Weigh In On Cryoport
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its holdings in Cryoport by 228.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock worth $36,000 after purchasing an additional 1,433 shares in the last quarter. Quarry LP bought a new stake in Cryoport during the second quarter worth approximately $40,000. Captrust Financial Advisors raised its holdings in Cryoport by 308.3% during the second quarter. Captrust Financial Advisors now owns 2,319 shares of the company’s stock worth $72,000 after purchasing an additional 1,751 shares in the last quarter. FMR LLC raised its holdings in Cryoport by 34.1% during the first quarter. FMR LLC now owns 2,935 shares of the company’s stock worth $70,000 after purchasing an additional 747 shares in the last quarter. Finally, State of Wyoming raised its holdings in Cryoport by 42.7% during the fourth quarter. State of Wyoming now owns 3,026 shares of the company’s stock worth $53,000 after purchasing an additional 905 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on Cryoport
About Cryoport
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
- Five stocks we like better than Cryoport
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Best Bear Market Funds: Top 3 Investment Options to Consider
- About the Markup Calculator
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Roth IRA Calculator: Calculate Your Potential Returns
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.